- Home
- SUGP vs AADI Comparison
SUGP vs AADI Comparison
Compare SUGP & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- AADI
- Stock Information
- Founded
- SUGP 1998
- AADI 2011
- Country
- SUGP Hong Kong
- AADI United States
- Employees
- SUGP N/A
- AADI N/A
- Industry
- SUGP
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- AADI Health Care
- Exchange
- SUGP NYSE
- AADI Nasdaq
- Market Cap
- SUGP 22.8M
- AADI 50.5M
- IPO Year
- SUGP 2024
- AADI N/A
- Fundamental
- Price
- SUGP $1.21
- AADI $2.15
- Analyst Decision
- SUGP
- AADI Hold
- Analyst Count
- SUGP 0
- AADI 3
- Target Price
- SUGP N/A
- AADI $1.75
- AVG Volume (30 Days)
- SUGP 76.3K
- AADI 116.7K
- Earning Date
- SUGP 11-02-2024
- AADI 11-06-2024
- Dividend Yield
- SUGP N/A
- AADI N/A
- EPS Growth
- SUGP N/A
- AADI N/A
- EPS
- SUGP 0.10
- AADI N/A
- Revenue
- SUGP $20,252,232.00
- AADI $23,817,000.00
- Revenue This Year
- SUGP N/A
- AADI $4.79
- Revenue Next Year
- SUGP N/A
- AADI $10.72
- P/E Ratio
- SUGP $11.60
- AADI N/A
- Revenue Growth
- SUGP N/A
- AADI 10.57
- 52 Week Low
- SUGP $0.98
- AADI $1.21
- 52 Week High
- SUGP $5.86
- AADI $5.70
- Technical
- Relative Strength Index (RSI)
- SUGP 44.20
- AADI 70.67
- Support Level
- SUGP $1.10
- AADI $1.90
- Resistance Level
- SUGP $1.38
- AADI $2.19
- Average True Range (ATR)
- SUGP 0.14
- AADI 0.10
- MACD
- SUGP 0.02
- AADI 0.01
- Stochastic Oscillator
- SUGP 28.21
- AADI 86.89
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.